keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Gastric inhibitory peptide (GIP) (22-51), a pro-atherogenic peptide comprised of 30 amino acids from the residues 22-51 of its precursor protein proGIP, is present in human plasma. It activates the degradation of IκB-α and the nuclear translocation of NF-κB in both macrophage-differentiated THP-1 cells and human aortic endothelial cells at a concentration of 1 µM. Additionally, in ApoE-/- mice, GIP (22-51) escalates the area of atherosclerotic lesions and plaque development in vivo.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | $ 55.00 | |
5 mg | Inquiry | $ 256.00 | |
10 mg | Inquiry | $ 483.00 | |
25 mg | Inquiry | $ 1,130.00 |
Description | Gastric inhibitory peptide (GIP) (22-51), a pro-atherogenic peptide comprised of 30 amino acids from the residues 22-51 of its precursor protein proGIP, is present in human plasma. It activates the degradation of IκB-α and the nuclear translocation of NF-κB in both macrophage-differentiated THP-1 cells and human aortic endothelial cells at a concentration of 1 µM. Additionally, in ApoE-/- mice, GIP (22-51) escalates the area of atherosclerotic lesions and plaque development in vivo. |
Synonyms | GIP (22-51), Glucose-dependent Insulinotropic Peptide (22-51) |
Molecular Weight | 3181.60 |
Formula | C140H226N44O41.XCF3COOH |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: Soluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Gastric Inhibitory Peptide (22-51) (human) TFA GIP (22-51) Glucose-dependent Insulinotropic Peptide (22-51) inhibitor inhibit